Richard Goldberg MD
机构: Professor emeritus, West Virginia University
每年引用次数
引用次数
引用: 74,127
H-指数: 114
I10-指数 : 413
出版物: 900
Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Richard Goldberg
Clinical advances in hematology & oncology 14 ( 1) 30 -33
2016
Sa1181 Role of Positive Technetium 99m-Labeled Red Blood Cell Scintigraphy in Brisk Gastrointestinal Bleeding to Predict Advanced Management and Correct Bleeding Site Identification
Brittain Little , Richard Heard , Charles N. Swift , Eric Fontenot
Gastroenterology 144 ( 5)
2013
Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.
Romain Cohen , Julien Taieb , Jack Fiskum , Greg Yothers
Journal of Clinical Oncology 39 ( 6) 642 -651
1
2021
Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?
Sameh Mikhail , Kristen Ciombor , Anne Noonan , Christina Wu
Oncotarget 6 ( 26) 22206 -22213
4
2015
O-0023 Phase 3 Correct Trial of Regorafenib in Metastatic Colorectal Cancer (mCRC)
Alberto Sobrero , Axel Grothey , Eric Van Cutsem , Salvatore Siena
Annals of Oncology 23 15 -16
1
2012
Colon Cancer in Older Adults
Laura Raftery , Hanna Kelly Sanoff , Richard Goldberg
Seminars in Oncology 35 ( 6) 561 -568
11
2008
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
Maxine D. Fisher , Leonard Saltz , Richard Goldberg , Richard Schilsky
Clinical Colorectal Cancer 1 ( 2) 82 -84
2001
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.
Amy J. French , Daniel J. Sargent , Lawrence J. Burgart , Nathan R. Foster
Clinical Cancer Research 14 ( 11) 3408 -3415
186
2008
End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal
Carmen Allegra , Charles Blanke , Marc Buyse , Richard Goldberg
Journal of Clinical Oncology 25 ( 24) 3572 -3575
56
2007
Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
Joel Tepper , Mark J. Krasna , Donna Niedzwiecki , Donna Hollis
Journal of Clinical Oncology 26 ( 7) 1086 -1092
966
2008
Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.
John Raymond Zalcberg , Qian Shi , Danielle Angela Ferraro , Jeffrey P. Meyers
Journal of Clinical Oncology 35 ( 15_suppl) 3582 -3582
2017
Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
Daniel Sargent , Alberto Sobrero , Axel Grothey , Michael J. O'Connell
Journal of Clinical Oncology 27 ( 6) 872 -877
367
2009
Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy.
James D. Ahlgren , Orrawin Trocki , John J. Gullo , Richard Goldberg
Cancer Investigation 9 ( 1) 27 -33
20
1991
Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803.
Nadine Jackson McCleary , Donna Niedzwiecki , Donna Hollis , Leonard B. Saltz
Cancer 116 ( 4) 957 -966
50
2010
A phase II trial and quality-of-life analysis of a 5-day regimen of oral 5-fluorouracil bracketed by a 7-day regimen of oral eniluracil in untreated patients with unresectable or metastatic colorectal carcinoma
TimothyJ. Hobday , MichelleR. Mahoney , DanielJ. Sargent , JeffA. Sloan
Clinical Therapeutics 24 47 -48
1
2002
Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).
Frank A. Sinicrope , Qian Shi , Fabienne Hermitte , Erica N Heying
Journal of Clinical Oncology 36 614 -614
6
2018
Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).
Amikar Sehdev , Donna Niedzwiecki , Alan P. Venook , Heinz-Josef Lenz
Journal of Clinical Oncology 36 638 -638
2
2018
Lower Cancer Incidence in Amsterdam-I Criteria Families Without Mismatch Repair Deficiency: Familial Colorectal Cancer Type X
Noralane M Lindor , Kari Rabe , Gloria M Petersen , Robert Haile
JAMA 293 ( 16) 1979 -1985
488
2005
Colorectal Tumour Microsatellite Instability Test Results: Perspectives from Patients
Noralane M Lindor , Jeff Sloan , Richard Goldberg , Deborah Bowen
Hereditary Cancer in Clinical Practice 2 ( 2) 69 -75
5
2004
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer
Ajay Goel , Takeshi Nagasaka , Christian N. Arnold , Toru Inoue
Gastroenterology 132 ( 1) 127 -138
253
2007